Abstract
Background: Dacomitinib is the first second-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to significantly improve ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
